Month: April 2019

What is Andarine (S4)?

S4, also known as Andarine, was developed by GTX, inc for the treatment of muscle wasting, osteoporosis, and benign prostatic hypertrophy [1]. In a rat model, 1.6mg/kg bodyweight has been shown to significantly increase bone mineral density, lean mass and body composition. 3mg/kg/day demonstrated significant increases in muscle mass [1, 2]. In the ovariectomized rat […]

About LGD-4033

LGD-4033 is a 3rd generation non-steroidal oral SARM with a high affinity for the androgen receptor (Ki of ~1 nM). It is currently the second most popular SARM on the market. Unlike testosterone which exerts anabolic effects by the same pathway, LGD-4033 has high selectivity for receptors in skeletal muscle, bone, and connective tissue, with […]